Dear editor,
We read with great interest the study by Philips et al. (1) , reporting on successful outcomes of the combination of streptomycin and rifampicin for two weeks followed by clarithromycin and rifampicin for six weeks in the treatment of Buruli ulcer (BU). Currently, drug treatment for BU consists of 8 weeks of intramuscular streptomycin and oral rifampicin. However, several recent studies, including the one by Philips et al. have described good outcomes with (partly) oral therapy using rifampicin and clarithromycin (1) (2) (3) , and a randomized controlled trial comparing the standard treatment with fully oral therapy is currently underway (4) .
Oral therapy is highly desirable, as intramuscular injections are painful and administration is logistically complicated in a rural African setting, sometimes forcing patients to travel several hours daily for 8 weeks to the nearest health facility. In addition, streptomycin carries a considerable risk for toxicity (5) .
These factors might negatively affect treatment compliance. The current WHO recommended strategy of early detection and decentralization of treatment favors community based care over clinical admission. However, compared to hospital based care, assuring compliance might be challenging, although adherence in BU under service conditions has never been studied. WHO issued a BU case record form that has been widely used in the context of National programs, with precise recording of drug dosages administered. We reviewed these forms at the BU clinic of Nkawie-Toase Hospital in Ghana. Of the 286 BU patients treated between 2008 and 2012, only 46% completed the recommended 56 doses of streptomycin and rifampicin. Non-compliance was significantly associated with self-referral, female gender, smaller lesions, and travel time.
We attempted to follow-up on these non-compliers, and were able to locate 57 former BU patients. When asked for their reasons of defaulting, 35% mentioned travel costs, 19% stopped coming when their ulcer got healed, and 14% defaulted due to the ototoxic adverse effects of streptomycin.
This large number of defaulters is perhaps not representative for BU drug treatment in Ghana. Yet, these findings indicate that non-compliance is in part related to streptomycin-both due to its toxicity, and the cumbersome and costly daily travel to the health facility for its administration. On the other hand, oral therapy might present inherent challenges in terms of compliance, as patients can be supplied with a full course of drugs to be taken at home, and patients will not be regularly seen at the health facility if no alternative from of directly observed treatment is provided.
The possible transition to an oral regimen has many apparent advantages, but can pose a challenge to national programs and local services in terms of compliance. Studies that combine or compare oral and parenteral regimens, such as the one by Phillips et al. can potentially shed more light on this issue, and we therefore urge authors of these studies to comment on their experiences with compliance in both modes of treatment. In addition, should oral therapy be implemented outside of a research setting, we suggest that compliance should be systematically monitored.
